|
Pubblico riconoscimento
• Mr. Warren Lammert e Kathy Corkins hanno contribuito al finanziamento di
alcune ricerche del Dr. Tarnopolsky sui disturbi mitocondriali e la Warren
Lammert and Kathy Corkin’s Clinic for Mitochondrial Disorders al McMaster
University Medical Center. Dr. Tarnopolsky ha ricevuto sostegni dal
Canadian Institute for Health Research and NSERC, Canada.
Esercizio e prevenzione
Esercizio
Prevenzione
|
Tabella 1. Farmaci da evitare in pazienti con disturbi mitocondriali. |
|
Sostanza
Statine Farmaci anti HIV ASA Acido valproico Metformina Alcool Fumo (nicotina) Cocaina, anfetamine, ecstasy |
Logica Possono ridurre il CoQ10. Inibiscono la gamma polimerasi (deplezione del mtDNA). Inibisce la funzione mitocondriale. Malattia di Reye nei bambini. Tossicità epatica, riduce la carnitina. Acidosi lattica dovuta a compromissione mitocondriale. Aumenta lo stress ossidativo, tossina mitocondriale. Inibisce complesso IV, danneggia i mitocondri Aumentano la domanda metabolica sulle cellule. |
Riferimenti 1. Taivassalo T, Haller RG. Exercise and training in mitochondrial miopatie. Med Sci Sports Exerc 2005;37:2094-101. 2. Taivassalo T, Gardner JL, Taylor RW, ed al.. Endurance training and detraining in mitochondrial miopatie due to single large-scale mtDNA deletions. Brain 2006;129:3391-401. 3. Jeppesen TD, Schwartz M, Olsen DB, ed al.. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006;129:3402-12. 4. Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, Shoubridge EA. Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 1999;8:1047- 52. 5. Roef MJ, de Meer K, Reijngoud DJ, ed al.. Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. Am J Clin Nutr 2002;75:237-44. 6. Sadun AA, Carelli V, Salomao SR, ed al.. Extensive investigazione of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol 2003;136:231-8. 7. Charlmers RM, Harding AE. A caso-control study of Leber's hereditary opticneuropathy. Brain 1996;119 ( Pt 5):1481-6. 8. Holloway AC, Cuu DQ, Morrison KM, Gerstein HC, Tarnopolsky MA. Transgenerational effects of fetal and neonatal exposure to nicotine. Endocrine 2007;31:254-9. 9. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. In vitro effects of nicotine on mitochondrial respirazione and superoxide anion generation. Brain Res 2001;900:72-9. 10. Sadun A. Acquired mitochondrial impairment as a cause of optic nerve disease. Trans Am Ophthalmol Soc 1998;96:881-923. 11. Warner RB, Lee AG. Leber hereditary optic neuropathy associated with use of ephedra alkaloids. Am J Ophthalmol 2002;134:918-20. 12. Cunha-Oliveira T, Rego AC, Cardoso SM, ed al.. Mitochondrial dysfunction and caspase activation in rat corticale neurons treated with cocaine or amphetamine. Brain Res 2006;1089:44-54. 13. Cardaioli E, Da Pozzo P, Gallus GN, ed al.. Leber's hereditary optic neuropathy associated with cocaine, ecstasy and telithromycin consumption. J Neurol 2007;254:255-6. 14. Djouadi F, Aubey F, Schlemmer D, ed al.. Bezafibrate increases very-longchain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasti and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 2005;14:2695-703. 15. Scatena R, Bottoni P, Vincenzoni F, ed al.. Bezafibrate induces a mitochondrial derangement in umana cell lines: a PPAR-independent mechanism for a peroxisome proliferator. Chem Res Toxicol 2003;16:1440-7. 16. Vladutiu GD, Simmons Z, Isackson PJ, ed al.. Genetic risk factors associated with lipidi-lowering drug-induced miopatie. Muscle Nerve 2006;34:153-62. 17. Zoll J, Ventura-Clapier R, Serrurier B, Bigard AX. Response of mitochondrial function to hypothyroidism in normal and regenerated rat muscoli scheletrici. J Muscle Res Cell Motil 2001;22:141-7. 18. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combinazione with additional nucleoside reverse transcriptase inibitori. Antivir Ther 2007;12:1075-85. 19. Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials 2003;4:11-9. 20. Jung TW, Lee JY, Shim WS, ed al.. Rosiglitazone protects umana neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 2006;340:221-7. 21. Strum JC, Shehee R, Virley D, ed al.. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007;11:45-51. 22. Caldwell SH, Patrie JT, Brunt EM, ed al.. The effects of 48 settimane of rosiglitazone on hepatocyte mitochondria in umana nonalcoholic steatohepatitis. Hepatology 2007;46:1101-7. 23. Lindberg M, Astrup A. The ruolo of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 2007;8:381-4. 24. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006;63:929-38. 25. Foster TS. Efficacy and sicurezza of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ 2007;33:111-7. 26. Kamenova P. Improvement dell'insulina sensitivity in patients with type 2 diabetes mellito after oral administration of alpha-lipoic acid. Hormones (Athens) 2006;5:251-8. 27. Ziegler D. Treatment of diabetic polyneuropathy: Update 2006. Ann N Y Acad Sci 2006;1084:250-66. 28. Gutknecht J. Aspirin, acetaminophen and proton trasporto attraverso phospholipid bilayers and mitochondrial membranes. Mol Cell Biochem 1992;114:3-8.
|